{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:08:42Z","timestamp":1790186922915,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,28]]},"DOI":"10.7759\/cureus.70394","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:54:41Z","timestamp":1727553281000},"source":"Crossref","is-referenced-by-count":1,"title":["Experience With Palbociclib in Metastatic Breast Cancer Patients Managed Under a Government Health Scheme at a Cancer Care Center in Southern India"],"prefix":"10.7759","author":[{"given":"Priyadharshini","family":"Eashwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak C","family":"Yadlapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Gullipalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: present scenario and the challenges ahead","volume":"13","author":"Mehrotra R","year":"2022","unstructured":"Mehrotra R, Yadav K. Breast cancer in India: present scenario and the challenges ahead. World J Clin Oncol. 2022, 13:209-18. 10.5306\/wjco.v13.i3.209","journal-title":"World J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e12567","article-title":"Breast cancer: the Indian scenario","volume":"38","author":"Gogia A","year":"2020","unstructured":"Gogia A, Deo S, Mathur S, Sharma D. Breast cancer: the Indian scenario. J Clin Oncol. 2020, 38:e12567. 10.1200\/JCO.2020.38.15_suppl.e12567","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu327.72","article-title":"Survival analysis of breast cancer patients treated at a tertiary care centre in Southern India","volume":"25","author":"Arumugham R","year":"2014","unstructured":"Arumugham R, Raj A, Nagarajan M, et al.. Survival analysis of breast cancer patients treated at a tertiary care centre in Southern India. Ann Oncol. 2014, 25:107. 10.1093\/annonc\/mdu327.72","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-breast-cancer-subtypes","article-title":"Subtypes of Breast Cancer","author":"Orrantia-Borunda E","year":"2022","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, et al.. Subtypes of Breast Cancer. Mayrovitz HN (ed): Exon Publications, Brisbane, AU; 2022. 10.36255\/exon-publications-breast-cancer-subtypes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_211_17","article-title":"Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: a retrospective study of 5436 women from a regional cancer center in South India","volume":"7","author":"Kumar RV","year":"2018","unstructured":"Kumar RV, Panwar D, Amirtham U, et al.. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: a retrospective study of 5436 women from a regional cancer center in South India. South Asian J Cancer. 2018, 7:7-10. 10.4103\/sajc.sajc_211_17","journal-title":"South Asian J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13017","article-title":"Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy","volume":"6","author":"Mouabbi JA","year":"2023","unstructured":"Mouabbi JA, Raghavendra AS, Bassett RL Jr, Hassan A, Tripathy D, Layman RM. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 2023, 6:e2313017. 10.1001\/jamanetworkopen.2023.13017","journal-title":"JAMA Netw Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype: a population-based study of 531,605 patients","volume":"20","author":"Rakha EA","year":"2020","unstructured":"Rakha EA, El-Sayed ME, Green AR, et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype: a population-based study of 531,605 patients. Clin Breast Cancer. 2020, 20:e589-99. 10.1200\/JCO.2007.12.2747","journal-title":"Clin Breast Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.04.010","article-title":"Clinical features and survival of single hormone receptor-positive breast cancer: a population-based study of 531,605 patients","volume":"20","author":"Lv M","year":"2020","unstructured":"Lv M, Mao Y, Song Y, et al.. Clinical features and survival of single hormone receptor-positive breast cancer: a population-based study of 531,605 patients. Clin Breast Cancer. 2020, 20:e589-99. 10.1016\/j.clbc.2020.04.010","journal-title":"Clin Breast Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update","volume":"37","author":"Burstein HJ","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, et al.. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update. J Clin Oncol. 2019, 37:423-38. 10.1200\/JCO.18.01160","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1039320","article-title":"Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"12","author":"Xie M","year":"2022","unstructured":"Xie M, Zhong Y, Yang Y, Shen F, Nie Y. Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: a meta-analysis with trial sequential analysis of randomized controlled trials. Front Oncol. 2022, 12:1039320. 10.3389\/fonc.2022.1039320","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000842","article-title":"Endocrine therapy-based treatments in hormone receptor-positive\/HER2-negative advanced breast cancer: systematic review and network meta-analysis","volume":"5","author":"Brand\u00e3o M","year":"2020","unstructured":"Brand\u00e3o M, Maurer C, Ziegelmann PK, et al.. Endocrine therapy-based treatments in hormone receptor-positive\/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open. 2020, 5:e000842. 10.1136\/esmoopen-2020-000842","journal-title":"ESMO Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020","volume":"29","author":"Cardoso F","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, et al.. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann Oncol. 2018, 29:1634-57. 10.1093\/annonc\/mdy192","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212579","article-title":"Palbociclib in metastatic breast cancer: current evidence and real-life data","volume":"8","author":"Serra F","year":"2019","unstructured":"Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019, 8:212579. 10.7573\/dic.212579","journal-title":"Drugs Context"},{"key":"ref15","article-title":"First-in-class CDK4\/6 inhibitor palbociclib could usher in a new wave of combination therapies for HR+, HER2- breast cancer","volume":"40","author":"McCain J","year":"2015","unstructured":"McCain J. First-in-class CDK4\/6 inhibitor palbociclib could usher in a new wave of combination therapies for HR+, HER2- breast cancer. Pharm Ther. 2015, 40:511-20.","journal-title":"Pharm Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn RS","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, et al.. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016, 375:1925-36. 10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5152\/ejbh.2019.4997","article-title":"Prevalence of molecular subtypes of breast cancer: a single institutional experience of 2062 patients","volume":"16","author":"Pandit P","year":"2020","unstructured":"Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R. Prevalence of molecular subtypes of breast cancer: a single institutional experience of 2062 patients. Eur J Breast Health. 2020, 16:39-43. 10.5152\/ejbh.2019.4997","journal-title":"Eur J Breast Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95758-1","article-title":"Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population","volume":"11","author":"Agrawal C","year":"2021","unstructured":"Agrawal C, Goyal P, Agarwal A, et al.. Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population. Sci Rep. 2021, 11:16236. 10.1038\/s41598-021-95758-1","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253722","article-title":"Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice","volume":"16","author":"Rath S","year":"2021","unstructured":"Rath S, Elamarthi P, Parab P, et al.. Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice. PLoS One. 2021, 16:e0253722. 10.1371\/journal.pone.0253722","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_235_18","article-title":"Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer","volume":"15","author":"Pareek A","year":"2019","unstructured":"Pareek A, Singh OP, Yogi V, Ghori HU, Tiwari V, Redhu P. Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer. J Cancer Res Ther. 2019, 15:971-5. 10.4103\/jcrt.JCRT_235_18","journal-title":"J Cancer Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/292661-experience-with-palbociclib-in-metastatic-breast-cancer-patients-managed-under-a-government-health-scheme-at-a-cancer-care-center-in-southern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:54:43Z","timestamp":1727553283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/292661-experience-with-palbociclib-in-metastatic-breast-cancer-patients-managed-under-a-government-health-scheme-at-a-cancer-care-center-in-southern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.70394","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}